10.1 | General production and post-production monitoring | 0 |
10.2 | Sources of production and post-production information | 0 |
10.3 | Reviewing collected information for safety relevance | 0 |
10.4 | Actions following information review | 0 |
4.1 | Ongoing risk management process across life cycle | 0 |
4.2.1 | Top management commitment to risk management | 0 |
4.2.2 | Policy for risk acceptability criteria | 0 |
4.2.3 | Review of risk management process suitability | 0 |
4.3 | Competence of risk management personnel | 0 |
4.4.1 | Content and upkeep of the risk management plan | 0 |
4.4.2 | Scope of the risk management plan | 0 |
4.4.3 | Assignment of responsibilities and authorities | 0 |
4.4.4 | Planning reviews of risk management activities | 0 |
4.4.5 | Criteria for risk acceptability in the plan | 0 |
4.4.6 | Method and criteria for overall residual risk | 0 |
4.4.7 | Planning verification of risk control measures | 0 |
4.4.8 | Collecting and reviewing production and post-production information | 0 |
4.5 | Risk management file and traceability | 0 |
5.1 | Risk analysis process steps | 0 |
5.2 | Intended use and foreseeable misuse | 0 |
5.3 | Characteristics affecting safety | 0 |
5.4.1 | Hazards and their origins | 0 |
5.4.2 | Hazardous situations in normal condition | 0 |
5.4.3 | Hazardous situations from faults | 0 |
5.4.4 | Random faults and their causes | 0 |
5.4.5 | Systematic faults and prevention | 0 |
5.4.6 | Security vulnerabilities and their effects | 0 |
5.4.7 | Event sequences and combinations | 0 |
5.5.1 | Estimating risk in general | 0 |
5.5.2 | Probability estimation and levels | 0 |
5.5.3 | Risks where probability is unknown | 0 |
5.5.4 | Severity levels and descriptors | 0 |
5.5.5 | Risk matrix examples and selection | 0 |
6 | Comparing estimated risks with acceptability criteria | 0 |
7.1.1 | Priority order for medical device design risk control | 0 |
7.1.2 | Risk control for manufacturing and outsourced processes | 0 |
7.1.3 | Using standards as risk control evidence | 0 |
7.2 | Verifying implementation and effectiveness of controls | 0 |
7.3 | Evaluating residual risk after controls | 0 |
7.4.1 | When benefit-risk analysis applies | 0 |
7.4.2 | Estimating the expected clinical benefit | 0 |
7.4.3 | Criteria applied to benefit-risk judgements | 0 |
7.4.4 | Weighing benefit against residual risk | 0 |
7.4.5 | Worked examples of benefit-risk conclusions | 0 |
7.5 | Reviewing risks created by risk control measures | 0 |
7.6 | Confirming completeness of risk control | 0 |
8.1 | Evaluating overall residual risk | 0 |
8.2 | Inputs to the overall evaluation | 0 |
8.3 | Approaches to evaluating overall residual risk | 0 |
9 | Risk management review | 0 |
A.1 | Purpose of the hazard identification questions | 0 |
A.2.1 | Intended use and manner of use | 0 |
A.2.10 | Modification of the patient environment | 0 |
A.2.11 | Measurements and their reliability | 0 |
A.2.12 | Interpretive output and algorithms | 0 |
A.2.13 | Use with other devices, medicines or technologies | 0 |
A.2.14 | Unwanted energy and substance outputs | 0 |
A.2.15 | Susceptibility to environmental influences | 0 |
A.2.16 | Effects of the device on its environment | 0 |
A.2.17 | Consumables and accessories | 0 |
A.2.18 | Maintenance and calibration | 0 |
A.2.19 | Software installation and updates | 0 |
A.2.2 | Implanted devices and in-body lifetime | 0 |
A.2.20 | Access to information through physical ports | 0 |
A.2.21 | Storage of data important to patient care | 0 |
A.2.22 | Restricted shelf life | 0 |
A.2.23 | Delayed and cumulative use effects | 0 |
A.2.24 | Mechanical forces on the device | 0 |
A.2.25 | What limits the device lifetime | 0 |
A.2.26 | Single-use devices | 0 |
A.2.27 | Decommissioning, disposal and data removal | 0 |
A.2.28 | Training and skills needed to install or use | 0 |
A.2.29 | How safety information reaches users | 0 |
A.2.3 | Contact with patients or other persons | 0 |
A.2.30 | New or changed manufacturing processes | 0 |
A.2.31 | Dependence on usability of the user interface | 0 |
A.2.32 | Alarm systems | 0 |
A.2.33 | Foreseeable misuse | 0 |
A.2.34 | Mobile and portable devices | 0 |
A.2.35 | Dependence on essential performance | 0 |
A.2.36 | Devices with a degree of autonomy | 0 |
A.2.37 | Output feeding a clinical decision | 0 |
A.2.4 | Materials and components in use | 0 |
A.2.5 | Energy delivered to or taken from the patient | 0 |
A.2.6 | Substances delivered to or drawn from the patient | 0 |
A.2.7 | Processing of biological material for reuse | 0 |
A.2.8 | Sterility and microbiological control | 0 |
A.2.9 | Routine cleaning and disinfection by the user | 0 |
B.1 | Techniques that support risk analysis | 0 |
B.2 | Preliminary hazard analysis early in development | 0 |
B.3 | Fault tree analysis from a top event | 0 |
B.4 | Event tree analysis of incident sequences | 0 |
B.5 | Failure mode and effects analysis by component | 0 |
B.6 | Hazard and operability study with guide words | 0 |
B.7 | Hazard analysis and critical control points | 0 |
C.1 | Policy, criteria, control and evaluation | 0 |
C.2 | Policy for criteria on risk acceptability | 0 |
C.3 | Setting criteria for risk acceptability | 0 |
C.4 | Practicability and residual risk magnitude | 0 |
C.5 | Residual risk compared against criteria | 0 |
C.6 | Examples of policy, criteria and evaluation links | 0 |
Clause-1 | Scope of the guidance | 0 |
Clause-Introduction | Aim and layout of the guidance | 0 |
D.1 | Difference between safety information and residual risk disclosure | 0 |
D.2 | Using information for safety as a control | 0 |
D.3 | Disclosing significant residual risks to users | 0 |
E.1 | Role of consensus standards in risk management | 0 |
E.2 | Using product safety standards in risk management | 0 |
E.3 | Aligning process standards with ISO 14971 | 0 |
F.1 | Security risks within the risk management process | 0 |
F.2 | Security terminology mapped to ISO 14971 | 0 |
F.3 | Harm scope and security related risks | 0 |
F.4 | How security risk management works | 0 |
F.5 | Ranking confidentiality, integrity and availability | 0 |
G.1 | Using existing information to build a risk management file | 0 |
G.2 | Planning remaining risk management activities | 0 |
G.3 | Building the initial risk management file | 0 |
H.1.1 | Applying ISO 14971 to IVD devices | 0 |
H.1.2 | Accounting for intermediaries and laboratory risk management | 0 |
H.2.1 | Intended use and reasonably foreseeable misuse | 0 |
H.2.2 | Characteristics related to patient safety | 0 |
H.2.3 | Known and foreseeable hazards to patients | 0 |
H.2.4 | Identifying and classifying potential harms | 0 |
H.2.5 | Defining hazardous situations for IVD risk analysis | 0 |
H.2.6 | Describing foreseeable sequences of events | 0 |
H.2.7 | Estimating the combined probability of harm | 0 |
H.3.1 | Focusing risk control on manufacturer influence | 0 |
H.3.2 | Designing for accurate and reliable results | 0 |
H.3.3 | Adding detection features to device and process | 0 |
H.3.4 | Providing effective information for safety | 0 |
H.3.5 | Standards as evidence for risk control | 0 |
H.3.6 | Training and educating device users | 0 |
H.4 | Weighing benefit against risk | 0 |
H.5.1 | Disclosing residual risks to users | 0 |
H.5.2 | Spelling out performance specifications | 0 |
H.5.3 | Disclosing device limitations | 0 |
H.5.4 | Deciding on generally known limitations | 0 |
H.6.1 | Setting up monitoring after production | 0 |
H.6.2 | Monitoring analytical performance data | 0 |
H.6.3 | Monitoring clinical performance and harms | 0 |
H.7.1 | Introduction to IVD risk scenarios | 0 |
H.7.2 | Worked example for laboratory analyser | 0 |
H.7.3 | Worked example for self-testing glucose device | 0 |
H.7.4 | Worked example for point-of-care delay | 0 |